Purpose Of Review: To analyze the status of precision medicine in atopic diseases.
Recent Findings: Atopic diseases are increasingly recognized as heterogeneous in nature and they can be quite different in severity, response to therapy, triggers, genetic back ground, ancestral risk and type of inflammation. This significant variability in the landscape of atopic diseases is not reflected in the common treatment guidelines that follow 'one fits all' approach for their management. Such an approach is largely based on minimal 'phenotype' elements, such as severity of disease and response to therapy and does not reflect the information accumulate in the last 20 years about particular pathogenic pathways (endotypes) leading to disease (phenotypes) based on biomolecular analysis of the single individuals. Accumulating data have defined asthma allergic rhinitis, food allergy based on their endotypes and clinically relevant phenotypes. In general, atopic diseases can be largely classified as high or low Th2 inflammatory status, which may explain the severity and response to therapy.
Summary: Precision medicine is aiming to use known endotype phenotype to guide specific individualized treatment. The work aimed in deep characterization of diseases to guide the disease management is crucial in light of the availability of ever more precise treatment able to target specific pathways.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ACI.0000000000000591 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Orismilast, a PDE4B/D inhibitor, in moderate-to-severe atopic dermatitis: Efficacy and safety from a multicenter, randomized, placebo-controlled, phase 2b dose-ranging study (ADESOS).
Br J Dermatol
January 2025
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, characterized by eczematous skin lesions and pruritus. There is an unmet need for effective first-line systemic therapies with good safety profiles, particularly oral medications. Orismilast is a novel first-in-class oral phosphodiesterase-4 (PDE4) B/D inhibitor under investigation for the treatment of moderate-to-severe AD.
View Article and Find Full Text PDF[A case of atopic dermatitis-the biopsychosocial view].
Dermatologie (Heidelb)
January 2025
Psychoneuroimmunologie Labor, Klinik für Psychosomatik und Psychotherapie, Justus-Liebig-Universität Gießen, Aulweg 123, 35385, Gießen, Deutschland.
Background: Atopic dermatitis is perhaps the most comprehensively studied skin disease in psychosomatic medicine and psychoneuroimmunology. Its biopsychosocial conceptualization incorporates psychodynamic as well as behavioral and systemic considerations. At the same time, there is also extensive biological knowledge of the neuroendocrine-immune control of barrier and immune function, characterized through animal experiments and translational clinical studies.
View Article and Find Full Text PDFBirthing parent adverse childhood experiences and risk of atopic diseases in 5-year-old children.
Front Allergy
January 2025
Department of Educational and Counselling Psychology and Special Education, University of British Columbia, Vancouver, BC, Canada.
Following up on previous findings from the All Our Families (AOF) cohort, the current study investigated the relationship between birthing parent history of adverse childhood experiences (ACEs) and child atopy, including asthma, allergy, and eczema, at five years of age. Potential indirect effects were explored. Participants completed the ACEs scale, validated questionnaires of anxiety and depression symptoms, and reported on their and their children's atopic disease history.
View Article and Find Full Text PDFImpact of Birth Order on Paediatric Allergic Diseases: A National Birth Cohort in Japan.
Clin Exp Allergy
January 2025
Department of Pediatrics, Okayama University, Graduate School of Medicine, Density and Pharmaceutical Science, Okayama, Japan.
Retrospective observational study shows accelerometers can monitor effects of canine pruritus treatment.
Am J Vet Res
January 2025
Waltham Petcare Science Institute, Waltham on the Wolds, Leicestershire, United Kingdom.
Objective: To evaluate the use of collar-mounted accelerometers to objectively monitor treatment outcomes in canine pruritus.
Methods: Observational data from 1,803 dogs from 2019 through 2023 were retrospectively analyzed to evaluate the efficacy of collar-mounted accelerometers to assess treatment efficacy for pruritic canine skin diseases. Accelerometer measurements were joined to electronic health records to establish symptoms, diagnoses, and interventions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!